GET DAILY SIGNALSMyriad Genetics (MYGN): Shifting Focus to Oncology and Key Product Milestones
Key Takeaways
- Product-launch momentum: The AI-enabled Prolaris + AI prostate test and the Precise MRD (minimal residual disease) assay are the central growth catalysts heading into 2027.
- Reimbursement milestone: A pending request for Medicare coverage (a Local Coverage Determination, or LCD) for Precise MRD in breast cancer could unlock a significant commercial opportunity if approved.
- Potential portfolio reshaping: Analyst commentary points to a possible divestiture of the prenatal business as a value-creating catalyst that could lift growth and margins.
- Macro sensitivity: Reimbursement trends, payer coverage decisions, and interest rates on the company's debt all influence near-term profitability.
- Divided analyst stance: Consensus sits at Hold, but price targets range widely — from $2.00 to $8.00 — reflecting sharply divergent views on execution risk.
Myriad's Strategic Positioning
Myriad Genetics (MYGN) operates across three reporting areas: the Cancer Care Continuum (hereditary cancer and tumor-profiling tests), Prenatal Health, and Mental Health (led by the GeneSight pharmacogenomic test). The company has anchored its medium-term strategy on oncology, positioning itself as a leader in hereditary cancer testing while expanding into tumor profiling, recurrence monitoring, and AI-assisted risk stratification.
Its competitive edge rests on breadth of menu — the MyRisk hereditary cancer panel now spans 63 genes across more than 11 cancer types — and on a growing body of clinical validation data. The Precise MRD platform, which uses ultrasensitive circulating-tumor DNA monitoring, represents an attempt to move Myriad into the faster-growing liquid-biopsy and recurrence-monitoring space, where competitors include Natera and Guardant Health. Structural risks include pricing pressure on average revenue per test, payer friction in hereditary cancer and prenatal volumes, and execution challenges that have triggered repeated guidance resets. I also checked this using Tickeron’s AI Trend Prediction Engine to get a sense of how the stock might respond to these shifts.
Major Catalysts on the Horizon
Several forward-looking developments are likely to shape investor sentiment over the coming quarters:
- Quarterly earnings (November 4, 2026): Craig-Hallum has argued that meeting or modestly exceeding third-quarter estimates while maintaining fiscal 2026 guidance is the primary near-term catalyst, with the firm raising its price target to $8 from $4 and suggesting shares "could double or more" over four to six months.
- Precise MRD reimbursement: Myriad submitted a request to the Molecular Diagnostics Program (MolDX) for a Medicare LCD covering Precise MRD in breast cancer. Management has noted that coverage timing — anticipated around 2027 — is a key variable outside the company's control.
- Prolaris + AI: The company's first AI-enabled prostate cancer test, developed with PATHOMIQ, launched in mid-2026 and could help defend share in a segment challenged by shifting clinical guidelines.
- FirstGene prenatal screen: A full commercial launch in the second half of 2026 is intended to reverse declining prenatal volumes and revenue.
- Potential prenatal divestiture: Craig-Hallum has flagged a deal to sell the prenatal business as a catalyst that would be "accretive to revenue growth, gross margin, and potentially cash flow."
- Analyst rating churn: The consensus rating is Hold, with an average price target near $4.11 across nine analysts. Recent moves have been mixed: TD Cowen raised its target to $4.50, while Piper Sandler double-downgraded the stock to Underweight with a $2 target and UBS initiated coverage at Neutral with a $3.60 target.
Industry and Macroeconomic Influences
Myriad's trajectory is tightly linked to the economics of molecular diagnostics. Reimbursement and payer coverage remain the dominant variables: decisions by insurers such as UnitedHealthcare on tests like GeneSight can materially move average revenue per test even when volumes grow. Broader healthcare utilization, physician ordering patterns, and the pace of adoption of liquid biopsy and AI-assisted diagnostics all shape demand.
On the macro side, higher interest rates raise the carrying cost of the company's debt — Myriad ended the second quarter of 2026 with about $115.2 million in cash and long-term debt — and can pressure valuations for unprofitable, growth-oriented diagnostics names. Inflation in labor and lab operating costs also affects margins, which management expects to fluctuate by quarter based on test mix and pricing. Finally, foreign-exchange exposure from international operations adds a modest but real translation risk.
2026 Outlook and Longer-Term Themes
Looking toward 2026 and beyond, Myriad's story is increasingly defined by its ability to convert a slate of new product launches into sustained, profitable growth. Management has signaled that 2026 is a "banner year" for catalysts that are leading indicators for 2027, with Precise MRD commercialization across breast, renal, and colorectal cancers planned for 2027 and the AI-enhanced Prolaris test broadening the oncology franchise.
Several long-term themes deserve attention. First, market expansion in minimal residual disease and recurrence monitoring could diversify revenue beyond hereditary cancer testing. Second, cost structure and margin sustainability will depend on disciplined operating expense management, as adjusted operating expenses are rising to fund sales-force expansion of more than 100 account executives. Third, technology transitions — particularly the integration of artificial intelligence into diagnostic workflows — could differentiate Myriad's offering but also invite new competition. Fourth, regulatory and reimbursement developments, including the Precise MRD LCD, remain binary swing factors.
Capital allocation will be pivotal. A potential prenatal divestiture, if executed, could simplify the portfolio and strengthen the balance sheet, while continued investment in oncology requires balancing near-term cash burn against long-term growth. Consensus expectations remain cautious, with analysts forecasting the company to remain unprofitable over the near term, but external price targets span a wide range — from $2.00 to $8.00 — underscoring how much of the outcome depends on execution and reimbursement timing rather than market growth alone.
Incorporating Tickeron’s Trend Prediction Engine
In my research process, I’ve turned to Tickeron’s Trend Prediction Engine to help assess whether names like this may trend bullish, bearish, or sideways over the coming weeks or months. The tool surfaces developing trends, possible breakouts or reversals, and provides historical context that adds a useful data layer when weighing product launches against analyst revisions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
MYGN sees MACD Histogram just turned negative
MYGN saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 12, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 38 instances where the indicator turned negative. In 35 of the 38 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for MYGN moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 22 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MYGN as a result. In 76 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MYGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
MYGN broke above its upper Bollinger Band on October 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
MYGN moved above its 50-day moving average on September 21, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MYGN crossed bullishly above the 50-day moving average on September 24, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 87%.
Following a +6.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where MYGN advanced for three days, in 198 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
The Aroon Indicator entered an Uptrend today. In 108 of 154 cases where MYGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.325) is normal, around the industry mean (63.909). P/E Ratio (-3.568) is within average values for comparable stocks, (1.606). Projected Growth (PEG Ratio) (1.236) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.448) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. MYGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MYGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutic and predictive medicine products
Industry MedicalSpecialties
Advertisement